Teceleukin
As of the edition of 20 October 2026, Teceleukin is a protein: marketed, first approved in 1992 (JP); acts on IL2RA, IL2RB and IL2RG.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1992
- Kind
- Protein
- Brand name
- Imunace
- First approved
- 31 December 1992 (JP)
- Approvals on record
- 2 in 1 region
- Holder of the most recent approval
- Shionogi
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
3 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product3 company-target rows are on route B because of Teceleukin.
See the 3 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Shionogi | Originator | 1992 to now |